PRODUCT INFORMATION



13,14-dihydro-15-keto Prostaglandin E₂-d_o

Item No. 19348

CAS Registry No.: 2750534-81-5

Formal Name: (Z)-7-((1R,2R,3R)-3-hydroxy-5-oxo-

2-(3-oxooctyl-5,5,6,6,7,7,8,8,8-d_o)

cyclopentyl)hept-5-enoic acid

Synonyms: 13,14-dihydro-15-keto PGE₂-d₉,

13,14-dihydro-oxo-PGE₂-d_o, PGEM-d_o

MF: $C_{20}H_{23}D_9O_5$

FW: 361.5

Chemical Purity: ≥98% (13,14-dihydro-15-keto PGE₂)

Deuterium

Incorporation: \geq 99% deuterated forms (d₁-d₉); \leq 1% d₀

A solution in methyl acetate Supplied as:

-20°C Storage: Stability: ≥2 years

Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

13,14-dihydro-15-keto Prostaglandin E_2 - d_0 (13,14-dihydro-15-keto PGE_2 - d_0) is intended for use as an internal standard for the quantification of 13,14-dihydro-15-keto PGE₂ (Item No. 14650) by GC- or LC-MS. The accuracy of the sample weight in this vial is between 5% over and 2% under the amount shown on the vial. If better precision is required, the deuterated standard should be quantitated against a more precisely weighed unlabeled standard by constructing a standard curve of peak intensity ratios (deuterated versus unlabeled).

13,14-dihydro-15-keto PGE₂-d₉ is supplied as a solution in methyl acetate. To change the solvent, simply evaporate the methyl acetate under a gentle stream of nitrogen and immediately add the solvent of choice. Solvents such as ethanol, DMSO, and dimethyl formamide purged with an inert gas can be used. The solubility of 13,14-dihydro-15-keto PGE₂-d₉ in these solvents is approximately 50 mg/ml.

Description

13,14-dihydro-15-keto-Prostaglandin E_2 - d_9 (13,14-dihydro-15-keto PGE $_2$ - d_9) is intended for use as an internal standard for the quantification of 13,14-dihydro-15-keto PGE, (Item No. 14650) by GC- or LC-MS. 13,14-dihydro-15-keto PGE_2 is a metabolite of PGE_2 (Item No. 14010) and the primary PGE_2 metabolite in plasma.^{1,2} It is formed from PGE $_2$ via a 15-keto PGE $_2$ intermediate by 15-oxo-PG Δ^{13} reductase.¹ Unlike PGE₂, 13,14-dihydro-15-keto PGE₂ does not bind effectively to the PGE₂ receptors EP₂ and EP₄ expressed in CHO cells (K_i s = 12 and 57 μ M, respectively) or induce adenylate cyclase activity in the same cells (EC_{so}s = >18 and >38 μ M, respectively). Levels of 13,14-dihydro-15-keto PGE₂ are increased in the plasma of women in the third trimester of pregnancy and in women during and immediately after labor and delivery.³ Levels of 13,14-dihydro-15-keto PGE₂ levels are decreased in tumor tissue compared to adjacent non-cancerous tissue isolated from patients with non-small cell lung cancer (NSCLC).4

References

- 1. Hamberg, M., and Samuelsson, B. J. Biol. Chem. 246(22), 6713-6721 (1971).
- Nishigaki, N., Negishi, M., and Ichikawa, A. Mol. Pharmacol. 50(4), 1031-1037 (1996).
- 3. Husslein, P. and Sinzinger, H. Br. J. Obstet. Gynaecol. 91(3), 228-231 (1984).
- 4. Hughes, D., Otani, T., Yang, P., et al. Cancer Prev. Res. (Phila) 1(4), 241-249 (2008).

WARNING
THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website

Copyright Cayman Chemical Company, 11/10/2023

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD ANN ARBOR, MI 48108 · USA PHONE: [800] 364-9897

[734] 971-3335

FAX: [734] 971-3640 CUSTSERV@CAYMANCHEM.COM WWW.**CAYMANCHEM**.COM